(CercleFinance.com) – Abionyx Pharma announces innovation aid of nearly 1 million euros from Bpifrance. The purpose of this aid is to support the drug candidate CER-001 dedicated to the treatment of a severe indication in ophthalmology.
This aid will contribute to the financing of studies of the drug candidate CER-001 and will be repayable at 0 rate subject to success from the last quarter of 2026 until the first quarter of 2031.
Abionyx Pharma specifies that the preclinical studies carried out to date have been a success and would like to thank Bpifrance for its long-standing assistance.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
